Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pazopanib 2 week · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part I and 2 week dosing Part II | OTHER | Part I - bevacizumab 3 infusions at 2 week intervals Part II - pazopanib dosing 2 weeks in 3-week cycles |
| Part I and 3 week dosing Part II | OTHER | Part I - bevacizumab 3 infusions at 2 week interval, Part II - pazopanib dosing 3 weeks in 3-week cycles |
| Name | Type | Description |
|---|---|---|
| Bevacizumab | DRUG | Bevacizumab - 3 infusions of 10mg/kg administered at 2 week intervals - Part I |
| Pazopanib 2 week | DRUG | Pazopanib for first 2 weeks of each 3-week cycles as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1). Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons. |
| Pazopanib 3 week | DRUG | Pazopanib throughout each 3-week cycle as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1). Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons. |
Inclusion Criteria: * Histologically (any histological subtype) or cytologically confirmed unresectable RCC with a clear cell component. * Experienced documented evidence of radiological progression based on Response Evaluation Criteria in Solid Tumors \[RECIST\] while on first line (or greater) RC...
Pazopanib 2 week is an investigational small molecule being studied for the treatment of renal cell carcinoma, a type of kidney cancer. It is currently in Phase 1 clinical development, meaning it is still being tested in early-stage trials to evaluate its safety and pharmacodynamic effects in patients.
Pazopanib 2 week is being developed by GSK plc, a global pharmaceutical company listed on the stock exchange under the ticker symbol GSK. The company is conducting clinical research on this drug candidate for renal cell carcinoma.
Pazopanib 2 week is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities, and is being studied in an early-stage clinical trial to assess its pharmacodynamic properties in patients with renal cell carcinoma.
Pazopanib 2 week has been studied in one completed clinical trial, identified as NCT00992121. This was an open-label, controlled, randomized Phase 1 pharmacodynamic study of bevacizumab and pazopanib in renal cell carcinoma, conducted in the United Kingdom with 11 adult participants.
Pazopanib 2 week is a specific formulation or dosing regimen of pazopanib, a small molecule drug. The clinical trial NCT00992121 evaluated pazopanib in combination with bevacizumab for renal cell carcinoma, and the '2 week' designation likely refers to the treatment duration studied in that trial.